Humacyte, Inc. Warrant (HUMAW)

The Russell 2000 index reached an all-time high after the Federal Reserve signaled potential interest rate cuts, boosting small-cap stocks and providing cheaper borrowing opportunities for smaller companies.

Humacyte reported Q2 2025 earnings with $0.30 million in GAAP revenue, falling short of $1.0 million analyst estimates. The company saw expanded hospital access for its lead product Symvess, with 82 civilian hospitals approved by quarter-end, and showed improved financial metrics through cost controls.

The Law Offices of Frank R. Cruz has filed class action lawsuits on behalf of shareholders of Wolfspeed, Humacyte, Xerox, and Zeta Global Holdings. The lawsuits allege that the companies made materially false and/or misleading statements about their business, operations, and prospects.